Zenlabs Ethica Peer Comparison

BSE: 530697

₹25.30

₹0.00 (0.00%)

As on 27-Aug-2026IST

Market cap

₹16 Cr

Revenue (TTM)

₹50 Cr

P/E Ratio

--

P/B Ratio

2.1

Div. Yield

0 %

Edit

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	16	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	50	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	-2.54	735.15	678.07	666.92	169.62
Net Margin (%)	-5.10	26.88	28.10	20.60	6.90
RoE (%)	-4.90	19.16	19.73	18.75	20.76
Price to Earnings	--	29.25	28.74	28.35	104.74
Price-To-Book	2.07	4.88	5.08	4.51	19.65

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	49.62	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	49.80	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	48.67	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	0.95	941.63	796.58	1,139.61	229.86
Depreciation	0.71	57.58	78.10	281.06	17.24
EBIT	0.25	884.05	718.48	858.55	212.62
Interest	0.76	7.69	0.88	190.64	5.72
Other Income	0.18	165.62	125.96	7.45	26.48
Exceptional Items	-2.08	-49.16	0.00	-17.24	-5.13
Profit before Tax	-2.41	992.82	843.56	658.12	228.25
Provision for Tax	0.13	257.67	165.49	-8.80	58.63
Profit after Tax	-2.54	735.15	678.07	666.92	169.62

Liabilities (₹ Cr)

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	8.51	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	1.57	91.50	28.74	1,392.75	134.50
Current Liabilities	27.12	627.48	385.94	2,077.10	981.81
Total Liabilities	40.62	4,911.11	3,207.85	6,862.28	1,879.19

Assets (₹ Cr)

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	1.55	770.28	1,291.22	5,617.77	42.47
Current Assets	35.10	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	40.62	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	11.88	2.50	0.55	2,421.66	0.00
Net Current Assets	7.98	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	0.07	363.79	0.64	64.29	98.41

Cashflow (₹ Cr)

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	3.83	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	0.14	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-3.08	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	0.88	383.07	59.32	103.72	30.57

Ratios

Profitability Ratios

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	5.96	26.21	26.22	13.59	21.29
ROE (%)	-4.90	19.16	19.73	18.75	20.76
ROA (%)	-6.52	14.95	18.69	9.26	9.67
EBIT Margin (%)	0.50	34.40	31.41	26.58	8.74
Net Margin (%)	-5.10	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	-1.81	10.69	15.01	9.59	31.10
EBIT Growth (%)	-80.46	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	-1,076.54	-9.09	19.61	62.68	-7.49
EPS Growth (%)	-279.69	14.40	17.73	67.41	-18.33
Book Value Growth (%)	2.98	17.30	23.77	10.19	7.70

Valuation Ratios

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	75.48	27.87	28.74	27.66	102.37
Price / Book Value	1.95	4.88	5.08	4.51	19.65
Dividend Yield (%)	0.00	1.60	0.16	0.55	0.51
EV/EBITDA	11.62	19.53	22.88	17.94	75.34
Market Cap (₹ Cr)	20.32	18,318.10	15,219.80	19,292.77	21,515.93

Solvency Ratios

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.02	0.00	0.00	0.24	0.00
Short term debt to equity ratio	1.06	0.00	0.00	0.14	--
Current Ratio	1.29	6.06	6.70	0.74	1.77
Quick Ratio	0.74	5.31	5.59	0.53	0.73
Interest Coverage	-2.17	130.11	959.59	4.45	40.90

Operating Efficiency Ratios

	Zenlabs Ethica	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	31.65	7.07	36.10	21.07	8.79
Asset Turnover	1.28	0.52	0.63	0.45	1.39
Receivable days	142.89	29.10	110.70	54.07	35.81
Inventory Days	89.06	69.53	65.86	32.16	82.25
Payable days	129.56	76.77	105.88	140.91	124.39
Cash Conversion Cycle	102.39	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly